| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chin-Chang Huang, Yi-Hsin Weng, Chin-Song Lu, Nai-Shin Chu, Tzu-Chen Ye. Dopamine transporter binding in chronic manganese intoxication. Journal of neurology. vol 250. issue 11. 2004-01-16. PMID:14648150. |
(99m)tc-trodat-1 is a cocaine analogue that can bind to the dopamine transporter (dat) site reflecting the function of presynaptic dopaminergic terminals. |
2004-01-16 |
2023-08-12 |
human |
| Lisa Won, Nancy Bubula, Suzanne Hessefort, Martin Gross, Alfred Helle. Enhanced survival of primary murine dopaminergic neurons induced by a partially purified cell lysate fraction from mouse-derived striatal hybrid monoclonal cells. Neuroscience letters. vol 353. issue 2. 2004-01-16. PMID:14664906. |
lysates of x61, a striatal-derived cell line, and a partially purified preparation from the lysate (uf4) contain a factor(s) capable of increasing the dopamine content of a mesencephalic-derived dopaminergic cell line (mn9d) and of cultures containing primary dopaminergic neurons. |
2004-01-16 |
2023-08-12 |
Not clear |
| Lisa Won, Nancy Bubula, Suzanne Hessefort, Martin Gross, Alfred Helle. Enhanced survival of primary murine dopaminergic neurons induced by a partially purified cell lysate fraction from mouse-derived striatal hybrid monoclonal cells. Neuroscience letters. vol 353. issue 2. 2004-01-16. PMID:14664906. |
treatment of cultures containing dopaminergic primary neurons grown in the absence of target cells over a 2 week period with x61 lysate or uf4 resulted in an elevation of dopamine levels of the cultures and of media homovanillic acid as well as a 2.0-fold (uf4) to 2.9-fold (x61 lysate) increase in the density of dopaminergic neurons in treated cultures. |
2004-01-16 |
2023-08-12 |
Not clear |
| Klaus Henning Krause, Stefan H Dresel, Johanna Krause, Christian la Fougere, Manfred Ackenhei. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neuroscience and biobehavioral reviews. vol 27. issue 7. 2004-01-15. PMID:14624805. |
for instance, dopaminergic psychostimulants, the drugs of first choice in adhd, interact directly with the dopamine transporter (dat). |
2004-01-15 |
2023-08-12 |
Not clear |
| Joshua T Dudman, Molly E Eaton, Anjali Rajadhyaksha, Wendy Macías, Muffadal Taher, Amy Barczak, Kimihiko Kameyama, Richard Huganir, Christine Konrad. Dopamine D1 receptors mediate CREB phosphorylation via phosphorylation of the NMDA receptor at Ser897-NR1. Journal of neurochemistry. vol 87. issue 4. 2004-01-14. PMID:14622123. |
addictive drugs such as amphetamine and cocaine stimulate the dopaminergic system, activate dopamine receptors and induce gene expression throughout the striatum. |
2004-01-14 |
2023-08-12 |
Not clear |
| Mei-Chuan Ku, Chin-Chang Huang, Hung-Chou Kuo, Tzu-Chen Yen, Chi-Jen Chen, Tung-Sheng Shih, Ho-Yuan Chan. Diffuse white matter lesions in carbon disulfide intoxication: microangiopathy or demyelination. European neurology. vol 50. issue 4. 2004-01-14. PMID:14634266. |
in addition, the (99m)tc-trodat-1 single photon emission computed tomography showed a normal uptake of the dopamine transporter, indicating a normal presynaptic dopaminergic pathway. |
2004-01-14 |
2023-08-12 |
Not clear |
| Nora Hagelberg, Heli Forssell, Sargo Aalto, Juha O Rinne, Harry Scheinin, Tero Taiminen, Kjell Någren, Olli Eskola, Satu K Jääskeläine. Altered dopamine D2 receptor binding in atypical facial pain. Pain. vol 106. issue 1-2. 2004-01-13. PMID:14581109. |
in seven patients with atypical facial pain, striatal presynaptic dopaminergic function was assessed with [18f]fdopa and dopamine d1 and d2 receptor availabilities with [11c]nnc 756 and [11c]raclopride, respectively. |
2004-01-13 |
2023-08-12 |
Not clear |
| Laura Cárdenas, Sylvain Houle, Shitij Kapur, Usoa E Bust. Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET. Synapse (New York, N.Y.). vol 51. issue 1. 2004-01-12. PMID:14579423. |
parenterally administered d-amphetamine has been used as a challenge drug to release dopamine, which in turns inhibits [11c]raclopride binding to dopaminergic d2 receptors as measured using positron emission tomography (pet) techniques. |
2004-01-12 |
2023-08-12 |
human |
| C Bishop, P D Walke. Combined intrastriatal dopamine D1 and serotonin 5-HT2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats. Neuroscience. vol 121. issue 3. 2004-01-09. PMID:14568025. |
loss of dopaminergic innervation to the striatum increases the sensitivity of dopamine (da) d1 and serotonin (5-ht) 5-ht2 receptor signaling. |
2004-01-09 |
2023-08-12 |
human |
| D J Brooks, K A Frey, K L Marek, D Oakes, D Paty, R Prentice, C W Shults, A J Stoess. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Experimental neurology. vol 184 Suppl 1. 2004-01-08. PMID:14597329. |
one approach, which has been extensively explored, is neuroimaging with radiotracers that interact with processes central to dopaminergic neurotransmission in the nigrostriatal dopaminergic axons-conversion of levodopa to dopamine through aromatic amino acid decarboxylase (aadc), [(18)f]fluorodopa pet, storage of dopamine in synaptic vesicles via the vesicular monoamine transporter 2 (vmat2), (+)-[(11)c]dihydrotetrabenazine pet, and reuptake of dopamine into axons via the dopamine transporter (dat), [(123)i]beta-cit spect, and a number of other pet and spect ligands. |
2004-01-08 |
2023-08-12 |
human |
| Paola Devoto, Giovanna Flore, Giorgio Longu, Luigi Pira, Gian Luigi Gess. Origin of extracellular dopamine from dopamine and noradrenaline neurons in the medial prefrontal and occipital cortex. Synapse (New York, N.Y.). vol 50. issue 3. 2004-01-06. PMID:14515337. |
our recent studies suggest that extracellular dopamine (da) in the cerebral cortex not only originates from dopaminergic terminals but is also coreleased with noradrenaline (na) from noradrenergic terminals [devoto et al. |
2004-01-06 |
2023-08-12 |
Not clear |
| F Blandini, A Mangiagalli, E Martignoni, A Samuele, R Fancellu, C Tassorelli, M Cosentino, F Marino, E Rasini, D Calandrella, G Riboldazzi, C Colombo, G M Frigo, G Napp. Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 24. issue 3. 2004-01-06. PMID:14598064. |
we investigated the effects of dopaminergic stimulation on anti-apoptotic protein bcl-2, pro-apoptotic enzyme caspase- 3, and anti-oxidant/anti-apoptotic enzyme cu/zn superoxide dismutase (sod) in human lymphocytes exposed to dopamine (da). |
2004-01-06 |
2023-08-12 |
human |
| Alexander Storch, Henry A Lester, Bernhard O Boehm, Johannes Schwar. Functional characterization of dopaminergic neurons derived from rodent mesencephalic progenitor cells. Journal of chemical neuroanatomy. vol 26. issue 2. 2004-01-05. PMID:14599663. |
a primary target for neurorestoration is parkinson's disease, characterized by a continuous loss of the dopaminergic neurons in the substantia nigra pars compacta leading to dopamine depletion in the striatum and subsequent clinical symptoms including bradykinesia, rigidity and tremor. |
2004-01-05 |
2023-08-12 |
human |
| Masahisa Yamada, Anthony S Basile, Irina Fedorova, Weilie Zhang, Alokesh Duttaroy, Yinghong Cui, Kathryn G Lamping, Frank M Faraci, Chu Xia Deng, Jürgen Wes. Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology. Life sciences. vol 74. issue 2-3. 2004-01-05. PMID:14607263. |
in addition, in vitro neurotransmitter release experiments indicated that m(5) receptors located on dopaminergic nerve terminals play a role in facilitating muscarinic agonist-induced dopamine release in the striatum, consistent with the observation that the dopaminergic neurons innervating the striatum almost exclusively express the m(5) receptor subtype. |
2004-01-05 |
2023-08-12 |
mouse |
| K L Double, G M Halliday, J Henderson, F M Griffiths, T Heinemann, P Riederer, M Gerlac. The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Experimental neurology. vol 184. issue 1. 2004-01-05. PMID:14637122. |
the absence of motoric disturbances or a striatal dopamine deficit in these animals suggests a subclinical dopaminergic lesion. |
2004-01-05 |
2023-08-12 |
rat |
| L M Gerstein, E L Dovedova, N S Popov. [Mechanism of nootropic digam action in hypofunction of brain dopaminergic system]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 103. issue 7. 2003-12-29. PMID:12938655. |
using microchemical methods for detection of dopamine (da), noradrenaline (na), serotonin (s) and its metabolite--5'-hydroxyindolilacetic acid (5'-hiaa) as well as the activity of neuromediator-utilising enzymes--mao a and b and enzymes of acetylcholine metabolism--cholinacetyltranspherase (chat) and acetylcholinesterase (ache), we revealed that synthetic gaba-derivative compound diagram (250 mg/kg during 10 days) normalized functioning of dopaminergic and acetylcholinergic systems in sensormotor cortex and caudate nucleus of wistar rats with haloperidol-induced (0.5 mg/kg during 30 days) bradykinesia. |
2003-12-29 |
2023-08-12 |
rat |
| Pershia Samadi, Laurent Grégoire, Paul J Bédar. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology. vol 45. issue 7. 2003-12-29. PMID:14573388. |
opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. |
2003-12-29 |
2023-08-12 |
monkey |
| Simone M Smits, Tiia Ponnio, Orla M Conneely, J Peter H Burbach, Marten P Smid. Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons. The European journal of neuroscience. vol 18. issue 7. 2003-12-19. PMID:14622207. |
nurr1, a member of the nuclear hormone receptor superfamily of transcription factors, is essential for establishing the dopaminergic phenotype, because expression of tyrosine hydroxylase (th), the rate-limiting enzyme in dopamine synthesis, requires nurr1. |
2003-12-19 |
2023-08-12 |
mouse |
| Thomas C Wetter, Juliane Winkelmann, Ilonka Eisenseh. Current treatment options for restless legs syndrome. Expert opinion on pharmacotherapy. vol 4. issue 10. 2003-12-18. PMID:14521483. |
dopaminergic agents including levodopa and dopamine agonists such as pergolide, pramipexole, cabergoline and ropinirole are regarded as the treatment of choice for idiopathic rls, however, the development of augmentation of symptoms, especially under levodopa therapy, may be a major problem. |
2003-12-18 |
2023-08-12 |
Not clear |
| Janet Romrell, Hubert H Fernandez, Michael S Oku. Rationale for current therapies in Parkinson's disease. Expert opinion on pharmacotherapy. vol 4. issue 10. 2003-12-18. PMID:14521485. |
doses of dopaminergic drugs can be escalated to treat parkinsonian symptoms, whereas selective dopamine blockers can be added to block psychosis. |
2003-12-18 |
2023-08-12 |
Not clear |